Clinical Influence of Nonadherence With Prophylactic Aspirin in Preventing Preeclampsia in High-Risk Pregnancies
- 1 April 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 75 (4), 1125-1132
- https://doi.org/10.1161/hypertensionaha.119.14107
Abstract
Download figure Download PowerPoint Aspirin nonadherence and its associated increase in cardiovascular and cerebrovascular events is well described; however, the prevalence of aspirin nonadherence among high-risk pregnant women at risk of preeclampsia and its influence on clinical outcomes remains unclear. Our study examined the prevalence of aspirin nonadherence and resistance among high-risk pregnant women quantitatively (platelet function analyzer 100 and plasma salicylic acid) and clinical outcomes relative to adherence. High-risk pregnant women were recruited across 3 centers in the South West Sydney Local Health District. Simultaneous clinic data, blood sample, and self-reported adherence assessment were prospectively collected at 4-week intervals from 12 to 36 weeks of gestation. Nonadherence was defined as normal platelet function analyzer 100 and nondetectable plasma salicylic acid in P=0.04), late-onset preeclampsia (41% versus 5%; OR, 4.2 [95% CI, 1.4–19.8]; P=0.04), intrauterine growth restriction (29% versus 5%; OR, 5.8; [95% CI, 1.2–8.3]; P=0.001), preterm delivery (27% versus 10%; OR, 5.2 [95% CI, 1.5–8.7]; P=0.008), and higher likelihood of increase in antihypertensives antenatally (60% versus 10%; OR, 4.6 [95% CI, 1.2–10.5]; P=0.003). Kaplan-Meier analysis demonstrated lower incidence of premature delivery in the ≥90% adherent group (HR, 0.3 [95% CI, 0.2–0.5]; PP<0.0001). Our data demonstrates that aspirin is an effective prophylactic agent with an absolute risk reduction of 51% (number needed to treat, 2) when adherence is ≥90%, compared with women with inadequate adherence. Women who were <90% adherent had higher rates of preeclampsia, intrauterine growth restriction, preterm delivery, and increase in antenatal antihypertensive requirements. Self-reported adherence does not accurately reflect actual adherence.Keywords
This publication has 32 references indexed in Scilit:
- Adherence to medication for chronic disorders during pregnancy: results from a multinational studyInternational Journal of Clinical Pharmacy, 2013
- Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical MarkersFetal Diagnosis and Therapy, 2012
- Medication use for chronic health conditions by pregnant women attending an Australian maternity hospitalAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2011
- Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early PregnancyObstetrics & Gynecology, 2010
- Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stentingAmerican Heart Journal, 2009
- Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of CardiologyEuropean Heart Journal, 2008
- Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patientsJournal of Translational Medicine, 2008
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- New South Wales population‐based birthweight percentile chartsJournal of Paediatrics and Child Health, 1996
- CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant womenThe Lancet, 1994